A study on a new drug for pancreatic cancer is being hailed as a potential breakthrough, with some experts suggesting it could significantly improve treatment options. The drug, a KRAS inhibitor, has shown promise in increasing survival rates for patients with one of the deadliest forms of cancer. Reports on the study's findings vary, with some outlets describing it as a "landmark" development that could double survival time, while others simply note that it offers new hope.